An update on the use of aspirin in primary prevention of cardiovascular disease.

We will review three large trials published in 2018, the ARRIVE Trial, ASCEND Trial, and ASPREE Trial that compared risks vs. benefits of aspirin in a variety of different primary prevention populations. We will also explore new guideline recommendations as a result of this new evidence. Finally, I’ll try and summarize the impact this will have on practice and how I personally am changing the way I’m managing aspirin use.